1. PharmAust is not aware of any information concerning it that...

1. PharmAust is not aware of any information concerning it that has not been announced which, ifknown by some in the market, could explain the recent trading in its securities.The Directors believe the recent trading in its shares is primarily due to the increased awareness inthe market place of PharmAust and the progress of the clinical trials of its primary drug candidate,Monepantel (MPL).In that context, PharmAust draws the attention of the ASX to its announcement on 15 July 2019that it had received ethics approval from the NSW Department of Primary Industry’s Secretary'sAnimal Care & Ethics Committee to recommence Phase II clinical trials in pet owners’ dogs withcancer using its newly formulated tablet.PharmAust also reported that the scaled manufacture of the new GMP quality tablet iscompleted.and anticipates delivery of the tablets from the USA in August/September and thenrecruitment can commence for the Phase II trials shortly thereafter. PharmAust aims to first treatdogs with B-cell lymphoma, the most prevalent canine cancer.The company is also pleased that its wholly owned subsidiary, Epichem Pty Ltd, has continued tobuild contract sales and income activities. On 2 July 2019, PharmAust announced that Epichemhad paid off its debt liability on time for a major state-of-the-art laboratory expansion undertakenEpichem’s revenues have made a significant upturn over the period 2015 to 2018, increasing 38%to $3.02 million in FY18, and forecast to exceed $3.7 million in FY19. Budgeted revenues for FY20are $4.2 million (subject to continuation of existing contracts). With the loan facility repaid the moneysaved on interest and principal will go straight to improving the bottom line.Finally, PharmAust notes that its largest shareholder has increased his holding in PAA from 5.16%to 7.49% and a Form 604 Notice of Change of Interests of Substantial Holder was released on theASX Company Announcements Platform this morning.2. (a) not applicable(b) not applicable(c) not applicable3. PAA is not aware of any other explanation for the recent trading in its securities.PharmAust Limited ABN 35 094 006 023. Suite 39, 1 Freshwater Parade, Claremont, Western AustraliaTel: 08 9202 6814 Fax: 08 9467 6111www.pharmaust.com4. PAA is in compliance with the Listing Rules of ASX including Listing Rule 3.1.5. PAA confirms that the responses to the questions above have been authorised and approved by itsboard.Yours sincerelySam WrightDirector & Company Secretary